Ensysce Biosciences, Inc.
ENSC
$2.17
-$0.30-12.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 153.15% | 685.23% | -62.94% | -61.28% | -64.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 153.15% | 685.23% | -62.94% | -61.28% | -64.07% |
| Cost of Revenue | 70.31% | -11.71% | -42.37% | -56.63% | -65.34% |
| Gross Profit | -45.49% | 216.80% | 33.63% | 52.98% | 65.70% |
| SG&A Expenses | -25.07% | -11.75% | 4.32% | -11.90% | 20.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.95% | -11.73% | -23.24% | -35.88% | -51.92% |
| Operating Income | -13.33% | 123.81% | 14.76% | 28.04% | 49.11% |
| Income Before Tax | -1.71% | 124.59% | 12.12% | -42.19% | 36.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.71% | 124.59% | 12.12% | -42.19% | 36.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -- | -- | -97.44% | 108.20% |
| Net Income | -1.74% | 124.61% | 11.84% | -42.44% | 36.19% |
| EBIT | -13.33% | 123.81% | 14.76% | 28.04% | 49.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 82.89% | 107.68% | 77.30% | 73.73% | 93.80% |
| Normalized Basic EPS | 82.88% | 107.68% | 77.22% | 75.26% | 93.31% |
| EPS Diluted | 82.89% | 107.68% | 77.30% | 73.73% | 93.80% |
| Normalized Diluted EPS | 82.88% | 107.68% | 77.22% | 75.26% | 93.31% |
| Average Basic Shares Outstanding | 494.63% | 220.56% | 287.73% | 439.97% | 923.27% |
| Average Diluted Shares Outstanding | 494.63% | 220.56% | 287.73% | 439.97% | 923.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |